Search hospitals > Michigan > Novi
Henry Ford Medical Center-Columbus
Claim this profileNovi, Michigan 48377
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
139 reported clinical trials
7 medical researchers
Summary
Henry Ford Medical Center-Columbus is a medical facility located in Novi, Michigan. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Henry Ford Medical Center-Columbus is involved with conducting 139 clinical trials across 328 conditions. There are 7 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, Eleanor M. Walker, and Stuart Gordon.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
PR positive
ER positive
Top PIs
Ding WangHenry Ford Hospital6 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
47 reported clinical trials
104 drugs studied
Haythem Y. AliHenry Ford Hospital6 years of reported clinical research
Expert in Skin Cancer
Studies Breast Cancer
42 reported clinical trials
107 drugs studied
Eleanor M. WalkerHenry Ford Hospital5 years of reported clinical research
Studies Skin Cancer
Studies Prostate Adenocarcinoma
19 reported clinical trials
60 drugs studied
Stuart GordonHenry Ford Health System3 years of reported clinical research
Studies Infective Cholangitis
Studies Primary Biliary Cirrhosis
13 reported clinical trials
16 drugs studied
Clinical Trials running at Henry Ford Medical Center-Columbus
Bladder Cancer
Skin Cancer
Breast Cancer
Lung Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Kidney Cancer
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Oropharyngeal Carcinoma
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Henry Ford Medical Center-Columbus?
Henry Ford Medical Center-Columbus is a medical facility located in Novi, Michigan. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Henry Ford Medical Center-Columbus is involved with conducting 139 clinical trials across 328 conditions. There are 7 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, Eleanor M. Walker, and Stuart Gordon.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.